Ohio State Study Shows HPV DNA Blood Test Could Tailor Surveillance for Throat Cancer Patients

Ohio State researchers find that a ctDNA blood test can track residual cancer after surgery, helping personalize treatment and reduce side effects for patients.

By: AXL Media

Published: Apr 3, 2026, 11:08 AM EDT

Source: Information for this report was sourced from Ohio State University Wexner Medical Center

Advancing Biomarker Precision in Oropharyngeal Oncology

A clinical breakthrough from The Ohio State University Wexner Medical Center is offering a new roadmap for the management of human papillomavirus (HPV)-associated throat cancer. By focusing on circulating tumor HPV DNA (ctDNA) in the blood, oncologists are gaining a high-definition view of a patient’s unique tumor biology that traditional imaging often misses. As more than 90% of throat cancer cases are now linked to HPV, the ability to track these viral genetic fragments provides an essential tool for personalizing the intensity of post-surgical therapies.

The Role of ctDNA in Post-Surgical Risk Assessment

The study followed 104 patients over a four-year period, specifically monitoring how ctDNA levels fluctuated before and after surgical intervention. Researchers found that while pretreatment levels are largely dictated by the tumor's biology and the patient's kidney function, postoperative levels serve as a critical indicator of residual cancer. Dr. Catherine Haring, a head and neck cancer specialist at OSUCCC – James, noted that this blood-based insight adds a vital layer of information to standard pathology reports, allowing for a more comprehensive understanding of a patient's recurrence risk.

Mitigating the Long-Term Side Effects of Over-Treatment

A primary driver of this research is the desire to preserve the quality of life for patients who frequently respond well to initial treatment but suffer from the grueling aftermath of radiation and chemotherapy. Common long-term complications include chronic dry mouth, difficulty swallowing, taste alterations, and hypothyroidism. By using ctDNA as a precise biomarker, doctors can potentially "de-escalate" treatment for low-risk patients, sparing them from unnecessary toxicities while ensuring that high-risk individuals receive the aggressive care required to prevent a relapse.